To overcome treatment evasion and reduce systemic effects, we developed CXCR4-targeted nanoparticles to co-deliver sorafenib with the MEK inhibitor AZD6244 in HCC. The gene discussed is CXCR4; the disease is hepatocellular carcinoma.